A company that developed a technology to address gastroesophageal reflux disease (GERD) by way of a procedure called Transoral Incisionless Fundoplication (TIF), just reported two-year data from its TIF U.S. registry, which was presented last week at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES; Los Angeles) meeting in Baltimore. Read More
